ADDENDUM NUMBER TWO TO DEVELOPMENT AND LICENSING AGREEMENT FOR SAFETY "SELDINGER" NEEDLE DEVICEDevelopment and Licensing Agreement • January 3rd, 2005 • Med-Design Corp • Surgical & medical instruments & apparatus
DealdocDevelopment and Licensing Agreement • September 14th, 2021
Development and licensing agreement for rHuPH20 (recombinant human hyaluronidase) in development of subcutaneous injectable formulation of recombinant human alpha 1-antitrypsin (rHuA1AT)
Fifth amendment to development and licensing agreement for oral parathyroid hormoneDevelopment and Licensing Agreement • February 5th, 2021
This Amendment No. 5 (“Amendment No. 5”) dated as of January 24, 2007 (the “Amendment Date”) to the License Agreement dated as of April 13, 2002, as amended on January 16, 2003, October 14, 2003, May 27, 2004 and September 23, 2004 (referred to hereinafter as the “Agreement”) by and between Unigene Laboratories, Inc. (“Unigene”), a Delaware corporation, and SmithKline Beecham Corporation, a GlaxoSmithKline Company (“GSK”), a Pennsylvania corporation.
First amendment to development and licensing agreement for oral parathyroid hormoneDevelopment and Licensing Agreement • February 15th, 2021
This Amendment No. 1 (“Amendment”) dated as of January 16, 2003 (“Amendment Date”), to the License Agreement (referred to hereinafter as the “Agreement”) entered into as of the 13th of April, 2002, by and between Unigene Laboratories, Inc. (“Unigene”), a Delaware corporation, and SmithKline Beecham Corporation, a GlaxoSmithKline company (“GSK”), a Pennsylvania corporation.
Development and licensing agreement for Enbrel biosimilarDevelopment and Licensing Agreement • December 30th, 2022
Musculoskeletal » Arthritis » Psoriatic arthritis Musculoskeletal » Arthritis » Rheumatoid arthritis Biological compounds
THIRD AMENDMENT (“Amendment No. 3”)Development and Licensing Agreement • February 25th, 2014 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • California
effective as of October 5, 2012 (“Amendment No. 3 Effective Date”) to the DEVELOPMENT AND LICENSING AGREEMENT dated as of September 27, 1996, as amended and supplemented by the FIRST AMENDMENT AND SUPPLEMENT effective as of November 15, 2005 and as amended by the SECOND AMENDMENT effective as of December 22, 2011 (the “Agreement”) by and between GILEAD SCIENCES, INC., a Delaware Corporation (“Gilead”), on the one hand, and F. HOFFMANN-LA ROCHE LTD, a corporation organized under the laws of Switzerland, and HOFFMANN-LA ROCHE INC., a corporation organized under the laws of New Jersey, on the other hand (collectively “Roche”). Capitalized terms used but not defined herein shall have the meanings assigned them in the Agreement.
EX-10.2 3 dex102.htm AMENDED AND RESTATED DEVELOPMENT AND LICENSING AGREEMENT CERTAIN INFORMATION IN THIS EXHIBIT IS SUBJECT TO A REQUEST FOR CONFIDENTIAL TREATMENT. IN ACCORDANCE WITH RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED,...Development and Licensing Agreement • May 5th, 2020 • New York
This Amended and Restated Development and Licensing Agreement (“Agreement”) is made and entered into as of the 25th day of February, 2004 (the “Effective Date”), between Tanox, Inc. (formerly known as Tanox Biosystems, Inc.), originally a Texas corporation and reincorporated as a Delaware corporation (“Tanox”), and Novartis Pharma AG, a company organized and existing under the laws of Switzerland (as successor-in-interest of Ciba-Geigy Limited) (“Novartis”). (Each of Novartis and Tanox is referred to herein individually as a “Party” and all are referred to collectively herein as the “Parties.”)
Avicanna Enters Agreement to Develop and License Cannabinoid Tablet Formulations for US Distributor PartnerDevelopment and Licensing Agreement • September 29th, 2020
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/
AMENDMENT NO. 4 TO DEVELOPMENT AND LICENSING AGREEMENTDevelopment and Licensing Agreement • August 11th, 2015 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDMENT NO. 4 TO THE DEVELOPMENT AND LICENSING AGREEMENT (the “Amendment”) is made as of August 5, 2015 (the “Amendment Date”), by and between Eagle Pharmaceuticals, Inc. (“Eagle”), and SciDose LLC, (“SciDose”), and amends the June 12, 2007 Development and Licensing Agreement (the “Original Agreement”), by and between Eagle and SciDose. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to such terms in the Original Agreement, as previously amended.
Fourth amendment to development and licensing agreement for oral parathyroid hormoneDevelopment and Licensing Agreement • November 7th, 2020 • Pennsylvania
This Amendment No. 4 (“Amendment No. 4”) dated as of May 27, 2004 (“Amendment Date”), to the License Agreement, entered into as of the 13th of April, 2002 and amended on January 14, 2003 and October 14, 2003 (referred to hereinafter as the “Agreement”), by and between Unigene Laboratories, Inc. (“Unigene”), a Delaware corporation, and SmithKline Beecham Corporation, a GlaxoSmithKline company (“GSK”), a Pennsylvania corporation.
Sixth amendment to development and licensing agreement for oral parathyroid hormoneDevelopment and Licensing Agreement • January 15th, 2022
This Amendment No. 6 (“Amendment No. 6”) dated as of April 9, 2008 (the “Amendment Date”) to the License Agreement dated as of April 13, 2002, as amended on January 27, 2007, January 16, 2003, October 14, 2003, May 27, 2004 and September 23, 2004 (referred to hereinafter as the “Agreement”) by and between Unigene Laboratories, Inc. (“Unigene”), a Delaware corporation, and SmithKline Beecham Corporation, a GlaxoSmithKline Company (“GSK”), a Pennsylvania corporation.
Development and licensing agreement for ralinepag and etrasimodDevelopment and Licensing Agreement • June 14th, 2024
Arena Pharmaceuticals and Everest Medicines have entered into a development and commercialization partnership for ralinepag and etrasimod in mainland China, Taiwan, Hong Kong, Macau, and South Korea.
Second amendment to development and licensing agreement for oral parathyroid hormoneDevelopment and Licensing Agreement • November 2nd, 2020
This Amendment No. 2 (“Amendment No. 2”) dated as of October 14, 2003 (“Amendment Date”), to the License Agreement (referred to hereinafter as the “Agreement”) entered into as of the 13th of April, 2002, by and between Unigene Laboratories, Inc. (“Unigene”), a Delaware corporation, and SmithKline Beecham Corporation, a GlaxoSmithKline company (“GSK”), a Pennsylvania corporation.
EXHIBIT ADevelopment and Licensing Agreement • March 3rd, 2006 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • California
FIRST AMENDMENT AND SUPPLEMENT (“this Amendment”) dated as of November 15, 2005 to the DEVELOPMENT AND LICENSING AGREEMENT (“the Original Agreement” and, as amended and supplemented by this Amendment, “the Agreement”) dated as of September 27, 1996, by and between GILEAD SCIENCES, INC., a Delaware Corporation (“Gilead”), on the one hand, and F. HOFFMANN-LA ROCHE LTD, a corporation organized under the laws of Switzerland, and HOFFMANN-LA ROCHE INC., a corporation organized under the laws of New Jersey, on the other hand (collectively “Roche”). Capitalized terms used but not defined herein shall have the meanings assigned them in the Original Agreement.
DEVELOPMENT AND LICENSING AGREEMENTDevelopment and Licensing Agreement • March 6th, 2012 • Ascend Acquisition Corp. • Semiconductors & related devices • California
This Development and Licensing Agreement (the “Agreement”) is made by and between Andover Fund, LLC (“Andover”), a Delaware corporation, and Infinitap Games, LLC (“Infinitap”), a California limited liability company.
SECOND AMENDMENT (“Amendment No. 2”)Development and Licensing Agreement • February 23rd, 2012 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • California
dated as of December 22, 2011 (“Amendment No. 2 Effective Date”) to the DEVELOPMENT AND LICENSING AGREEMENT dated as of September 27, 1996, as amended and supplemented by the FIRST AMENDMENT AND SUPPLEMENT effective as of November 15, 2005 (the “Agreement”) by and between GILEAD SCIENCES, INC., a Delaware Corporation (“Gilead”), on the one hand, and F. HOFFMANN-LA ROCHE LTD, a corporation organized under the laws of Switzerland, and HOFFMANN-LA ROCHE INC., a corporation organized under the laws of New Jersey, on the other hand (collectively “Roche”). Capitalized terms used but not defined herein shall have the meanings assigned them in the Agreement.
Development and licensing agreement for stroke using multistem therapyDevelopment and Licensing Agreement • December 2nd, 2024
Hospital care » Surgery » Orthopedics Respiratory » Acute respiratory distress syndrome Regenerative medicine » Cell therapy Regenerative medicine » Stem cells
Heraeus Medical GmbH and BioTime Subsidiary OrthoCyte Corporation Enter Into Exclusive Worldwide Development and Licensing AgreementsDevelopment and Licensing Agreement • September 30th, 2015 • Biotime Inc • Biological products, (no disgnostic substances)
HANAU, Germany & ALAMEDA, Calif.--(BUSINESS WIRE)--September 30, 2015--Heraeus Medical GmbH, one of the leading companies in the field of bone cement and biomaterials for elective orthopedic and trauma surgery, and BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company focused on its pluripotent stem cell technology, today announced that BioTime’s subsidiary OrthoCyte Corporation and Heraeus Medical have entered into exclusive development and worldwide licensing agreements for the development of innovative bone grafting therapies based on the use of BioTime’s proprietary PureStem® human embryonic progenitor cell technology. Under the terms of the development agreement, Heraeus Medical would make an initial $1 million USD upfront payment to OrthoCyte, and additional payments upon OrthoCyte’s attainment of certain product development milestones, and Heraeus will fund all ongoing product development activities through IND submission.
Second amendment to development and licensing agreement for program in bladder cancerDevelopment and Licensing Agreement • December 12th, 2021
Development and licensing agreement for program in bladder cancer First amendment to development and licensing agreement for program in bladder cancer
Development and licensing agreement for RON (Recepteur d’Origine Nantais) receptorDevelopment and Licensing Agreement • January 29th, 2022
n/d : Centocor Ortho Biotech will also fund certain research conducted by AVEO, including translational research studies using its Human Response Platform to identify biomarkers for patients most likely to benefit from treatment with RON-targeted antibodies
Development and licensing agreement for Virtue Sirolimus-Eluting Balloon (SEBDevelopment and Licensing Agreement • July 10th, 2024
Terumo has secured exclusive global development and commercialization rights to Virtue Sirolimus-Eluting Balloon (SEB) for percutaneous coronary interventions by entering into a strategic partnership with Orchestra BioMed.
AMENDMENT TO DEVELOPMENT AND LICENSING AGREEMENTDevelopment and Licensing Agreement • December 14th, 2022 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDMENT TO THE DEVELOPMENT AND LICENSING AGREEMENT (the “Amendment”) is made as of December 9, 2022 (the “Amendment Date”) and effective as of October 1, 2022, by and between Eagle Pharmaceuticals, Inc. (“Eagle”), and Robert One, LLC, (“Robert One”), and amends the February 13, 2009 Development and Licensing Agreement, by and between Eagle and Robert as amended on May 22, 2009, December 23, 2010, and August 5, 2015 (collectively the “Agreement”). Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to such terms in the Agreement.
Third amendment to development and licensing agreement for oral parathyroid hormoneDevelopment and Licensing Agreement • December 17th, 2020
This Amendment No. 3 (“Amendment No. 3”) dated as of 23 Sept., 2004 (“Amendment Date”), to the License Agreement, entered into as of the 13th of April, 2002, and amended on January 16, 2003 and October 14, 2003 (referred to hereinafter as the “Agreement”), by and between Unigene Laboratories, Inc. (“Unigene”), a Delaware corporation, and SmithKline Beecham Corporation, a GlaxoSmithKline company (“GSK”), a Pennsylvania corporation.
Development and licensing agreement for TAG-72Development and Licensing Agreement • June 15th, 2021
The agreement grants Enlyton exclusive worldwide rights to develop 3E8, a humanized monoclonal antibody (mAb) designed to target the tumor-associated glycoprotein 72 (TAG-72) antigen, for use in cancer detection and targeted drug delivery.
CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. DEVELOPMENT AND LICENSING AGREEMENT This Development and License Agreement ("Agreement") is entered...Development and Licensing Agreement • April 14th, 2003 • Tower Semiconductor LTD • Semiconductors & related devices • California
AMENDMENT NO. 2 TO DEVELOPMENT AND LICENSING AGREEMENTDevelopment and Licensing Agreement • August 11th, 2015 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDMENT NO. 2 TO THE DEVELOPMENT AND LICENSING AGREEMENT (the “Amendment”) is made as of August 5, 2015 (the “Amendment Date”), by and between Eagle Pharmaceuticals, Inc. (“Eagle”), and Robert One, LLC, (“Robert”), and amends the February 13, 2009 Development and Licensing Agreement (the “Original Agreement”), by and between Eagle and Robert as amended on December 23, 2010. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to such terms in the Original Agreement.
Development and licensing agreement for abuse-deterrent oral hydrocodone opioidDevelopment and Licensing Agreement • February 1st, 2022 • New York
Egalet announced that the investigational new drug (IND) application submitted by Shionogi to the U.S. Food and Drug Administration (FDA) for the hydrocodone product candidate, S-718632 is now open and active triggering a $10 million milestone payment to Egalet.
Development and licensing agreement for oral formulation of insulinDevelopment and Licensing Agreement • January 31st, 2022 • New York
Emisphere and Novo Nordisk entered an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins using Emisphere's Eligen® Technology.
